- Home
- LSF vs ANL Comparison
LSF vs ANL Comparison
Compare LSF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSF | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 52.0M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LSF | ANL |
|---|---|---|
| Price | $2.09 | $1.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 106.7K | 28.8K |
| Earning Date | 11-10-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.02 | $0.88 |
| 52 Week High | $8.96 | $2.99 |
Technical Indicators
Market Signals| Indicator | LSF | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 61.06 |
| Support Level | $2.02 | $0.88 |
| Resistance Level | $2.52 | $1.59 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 6.58 | 92.82 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.